5-hydroxytryptophan (5-HTP) is an amino acid intermediate in the biosynthesis of serotonin. In humans, the essential amino acid L-tryptophan is converted by tryptophan hydroxylase to 5-HTP, which is subsequently decarboxylated to serotonin (5-hydroxytryptamine, or 5-HT). Because serotonin participates in the regulation of mood, sleep, appetite, gastrointestinal function and other physiological processes, supplemental 5-HTP has long attracted interest as a strategy for increasing substrate availability for serotonin synthesis.1
Unlike serotonin itself, 5-HTP can cross the blood-brain barrier. It also bypasses the tryptophan-hydroxylase step in serotonin synthesis, which has contributed to the rationale for its use as a serotonergic nutritional intervention. However, the biological plausibility of 5-HTP is considerably stronger than the modern clinical evidence supporting many of its commonly promoted uses.2
For practitioners, that distinction is important. 5-HTP has been investigated for depression, sleep disorders and several other serotonin-associated conditions, but much of the clinical literature is older, involves small samples, or does not meet contemporary standards for randomized controlled trials. It should therefore be approached as a potentially active serotonergic compound rather than as a broadly proven treatment.
Mechanism of Action and Serotonin Synthesis
5-HTP is produced endogenously from L-tryptophan and then converted to serotonin by aromatic L-amino acid decarboxylase. Supplemental 5-HTP can increase the amount of precursor available for serotonin production in both peripheral tissues and the central nervous system.2
This pathway differs from selective serotonin reuptake inhibitors (SSRIs), which primarily increase serotonergic signaling by inhibiting serotonin reuptake. 5-HTP instead provides additional substrate for serotonin synthesis. Peripheral conversion is clinically relevant because orally administered 5-HTP can be converted to serotonin before reaching the brain. This contributes to gastrointestinal adverse effects and complicates assumptions about the relationship between oral dose and central serotonergic activity.2
Serotonin is also a precursor to melatonin, providing a mechanistic rationale for interest in 5-HTP as a sleep-support compound. Nevertheless, demonstrating an effect on a biochemical pathway does not by itself establish clinically meaningful improvement in mood or sleep.
Mood and Depression
Depression is perhaps the best-known clinical application of 5-HTP, but the evidence requires cautious interpretation. Numerous trials were conducted during the 1960s through 1980s, often using methodologies that would not meet current research standards.
A Cochrane systematic review evaluating tryptophan and 5-HTP for depression identified 108 potentially relevant studies, but only two trials involving a total of 64 participants met the review’s quality criteria. The pooled findings favored the active interventions over placebo, but the reviewers concluded that the evidence was insufficiently robust to recommend widespread clinical use.3
A related meta-analysis reached essentially the same conclusion: the available data suggested a possible antidepressant effect, but the very small number of adequately designed studies and the possibility of publication bias prevented reliable conclusions.4
Older comparative research also produced mixed findings. In one double-blind study involving 30 patients, 5-HTP administered with a peripheral decarboxylase inhibitor was compared with imipramine, with no significant difference in efficacy reported between the treatments. Gastrointestinal adverse effects were more characteristic of the 5-HTP regimen.5
More recent evidence remains limited. A small randomized, double-blind crossover study in 25 patients with Parkinson’s disease reported improvement in depressive symptoms with 50 mg/day of 5-HTP compared with placebo, but the investigators characterized the findings as preliminary and called for larger, longer studies.6
Accordingly, practitioners should avoid presenting 5-HTP as an established antidepressant or as a replacement for evidence-based treatment of major depressive disorder.
Sleep Support
Because serotonin participates in sleep regulation and serves as a biochemical precursor to melatonin, 5-HTP is frequently included in sleep-support formulations. The mechanistic rationale is plausible, and older clinical studies investigated 5-HTP in patients with sleep disturbances.17
However, compared with many contemporary sleep interventions, the evidence base is relatively limited. Much of the frequently cited literature is several decades old, and differences in populations, doses and study design make it difficult to establish an evidence-based standard dose for insomnia.
Clinically, 5-HTP may be considered when a practitioner is specifically targeting serotonergic pathways in a patient with sleep complaints, but claims that it reliably treats insomnia or improves sleep architecture should be tempered by the limited quality and quantity of controlled human evidence.
Appetite and Other Potential Applications
Serotonin participates in satiety and appetite signaling, which has prompted research into 5-HTP for food intake and weight management. 5-HTP has also been explored in conditions ranging from headache and fibromyalgia to neurological and psychiatric disorders. These applications remain investigational, and evidence varies substantially by condition.
The breadth of proposed uses can create a misleading impression that 5-HTP has been clinically established across multiple indications. A more appropriate practitioner interpretation is that 5-HTP is biologically active and has been investigated in several serotonin-associated conditions, while high-quality evidence supporting routine therapeutic use remains limited.
Dosing Considerations
Clinical studies have used widely varying doses. Older depression studies frequently administered approximately 150-300 mg/day, while some contemporary investigations have used substantially lower doses. A Parkinson’s disease crossover trial, for example, evaluated 50 mg/day for four weeks.56
Commercial supplements commonly provide approximately 50-100 mg per capsule or serving. Because gastrointestinal effects may be dose dependent, lower initial doses and gradual titration are sometimes used in clinical practice. However, there is no universally established therapeutic dose for mood, sleep or other common applications.
Practitioners should distinguish between doses used in research and individualized clinical recommendations, particularly because concurrent medications and other serotonergic supplements can materially change the safety profile.
Safety, Serotonin Syndrome and Drug Interactions
Safety considerations are particularly important with 5-HTP because it directly participates in serotonin synthesis. Gastrointestinal symptoms, including nausea and related digestive complaints, are among the most consistently reported adverse effects and may increase with dose.5
More importantly, combining 5-HTP with medications or supplements that increase serotonergic activity can theoretically produce excessive serotonergic signaling. Reviews of 5-HTP have specifically identified serotonin syndrome as an important safety consideration.2
Practitioners should therefore carefully review use of SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants with serotonergic activity, certain migraine medications, tramadol and other serotonergic drugs before recommending 5-HTP. The absence of extensive interaction trials should not be interpreted as evidence that combinations are safe.
The historical association between tryptophan-related products and eosinophilia-myalgia syndrome has also influenced safety discussions. Systematic reviewers have noted that the relationship between 5-HTP products and this rare but potentially serious syndrome has not been fully resolved.3
Pregnancy and lactation, significant psychiatric illness, polypharmacy and use in children warrant additional caution because adequate safety data are lacking.
Potential Practitioner Applications
Mood support: 5-HTP may be considered as a serotonergic nutritional intervention, but evidence is insufficient to position it as a treatment for major depressive disorder.
Sleep support: its relationship to serotonin and melatonin provides a plausible rationale, although controlled clinical evidence remains limited.
Patients with low serotonergic dietary substrate or targeted nutritional strategies: 5-HTP bypasses the conversion of tryptophan to 5-HTP, but clinical benefit cannot be inferred solely from this biochemical advantage.
Adjunctive research settings: 5-HTP continues to attract interest as a strategy for enhancing serotonergic activity, including investigation of slow-release formulations.
Clinical Perspective
5-HTP is a useful example of the difference between biochemical plausibility and established clinical efficacy. Its position immediately upstream of serotonin makes its mechanism straightforward and provides a rational basis for investigating effects on mood, sleep and appetite. Yet the clinical evidence has not developed to the same degree as the mechanistic rationale.
Older studies suggest possible antidepressant effects, and selected newer trials continue to produce intriguing findings. Nevertheless, systematic reviews have emphasized that the small number of high-quality controlled studies prevents firm conclusions.34
For practitioners, the most important consideration may be that 5-HTP should not be treated as an innocuous amino acid supplement. It is a biologically active serotonin precursor with meaningful potential for pharmacologic interaction. Appropriate medication review is particularly important before use.
At present, 5-HTP is best viewed as a targeted nutraceutical with a plausible serotonergic mechanism and preliminary evidence for selected applications, rather than as an established therapy for depression, insomnia or other serotonin-associated disorders.
References
- Cho C, et al. A comprehensive review of nutritional influences on the serotonergic system. Advances in Nutrition. 2025. PMID: 40998119.
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics. 2006;109(3):325-338. PMID: 16023217.
- Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews. CD003198. PMID: 11687048.
- Shaw K, Turner J, Del Mar C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Australian & New Zealand Journal of Psychiatry. 2002;36(4):488-491. PMID: 12169147.
- Angst J, Woggon B, Schoepf J. The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Archiv für Psychiatrie und Nervenkrankheiten. 1977;224(2):175-186. PMID: 336002.
- Meloni M, Puligheddu M, Carta M, et al. Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson’s disease: a preliminary finding. European Journal of Neurology. 2020;27(5):779-786. PMID: 32067288.
- Soulairac A, Lambinet H. Effect of 5-hydroxytryptophan, a serotonin precursor, on sleep disorders. Annales Médico-Psychologiques. 1977;1(5):792-798. PMID: 339807.
- Jacobsen JPR, et al. Adjunctive 5-hydroxytryptophan slow-release for treatment-resistant depression: clinical and preclinical rationale. Trends in Pharmacological Sciences. 2016. PMID: 27692695.
